-
1Academic Journal
المؤلفون: Sood, S L, Cheng, D, Shapiro, A D, Kessler, C M, Key, N S, Quon, Doris V, Eyster, M E, Manco-Johnson, Marilyn J, Kempton, Christine L, Cuker, Adam, Ragni, M V, Gill, J C, Kuriakose, Philip, Von Drygalski, A, Kouides, P, Escobar, M A, Wheeler, A P, Wang, T, Leissinger, C A, Galdzicka, S, Konkle, B
المصدر: Hematology/Oncology Meeting Abstracts
-
2Academic Journal
المؤلفون: Sood, S. L., James, A. H., Ragni, M. V., Shapiro, A. D., Witmer, C., Vega, R., Bolgiano, D., Konkle, B. A.
مصطلحات موضوعية: Oncology and Hematology, Health Sciences
وصف الملف: application/pdf
Relation: Sood, S. L.; James, A. H.; Ragni, M. V.; Shapiro, A. D.; Witmer, C.; Vega, R.; Bolgiano, D.; Konkle, B. A. (2016). "A prospective study of von Willebrand factor levels and bleeding in pregnant women with type 1 von Willebrand disease." Haemophilia 22(6): e562-e564.; https://hdl.handle.net/2027.42/134934; Haemophilia; Drury‐Stewart DN, Lannert KW, Chung DW et al. Complex changes in von Willebrand factor‐associated parameters are acquired during uncomplicated pregnancy. PLoS ONE 2014; 9: e112935.; Huq FY, Kulkarni A, Agbim EC, Riddell A, Tuddenham E, Kadir RA. Changes in the levels of factor VIII and von Willebrand factor in the puerperium. Haemophilia 2012; 18: 241 – 5.; Cadroy Y, Grandjean H, Pichon J et al. Evaluation of six markers of haemostatic system in normal pregnancy and pregnancy complicated by hypertension or pre‐eclampsia. Br J Obstet Gynaecol 1993; 100: 416 – 20.; Kirtava A, Drews C, Lally C, Dilley A, Evatt B. Medical, reproductive and psychosocial experiences of women diagnosed with von Willebrand’s disease receiving care in haemophilia treatment centres: a case–control study. Haemophilia 2003; 9: 292 – 7.; James AH, Jamison MG. Bleeding events and other complications during pregnancy and childbirth in women with von Willebrand disease. J Thromb Haemost 2007; 5: 1165 – 9.; Chi C, Bapir M, Lee CA, Kadir RA. Puerperal loss (lochia) in women with or without inherited bleeding disorders. Am J Obstet Gynecol 2010; 203 ( 56 ): e1 – 5.; Kouides PA, Phatak PD, Burkart P et al. Gynaecological and obstetrical morbidity in women with type I von Willebrand disease: results of a patient survey. Haemophilia 2000; 6: 643 – 8.; Sanchez‐Luceros A, Meschengieser SS, Marchese C et al. Factor VIII and von Willebrand factor changes during normal pregnancy and puerperium. Blood Coagul Fibrinolysis 2003; 14: 647 – 51.; Sie P, Caron C, Azam J et al. Reassessment of von Willebrand factor (VWF), VWF propeptide, factor VIII: C and plasminogen activator inhibitors 1 and 2 during normal pregnancy. Br J Haematol 2003; 121: 897 – 903.; Goodeve A, Eikenboom J, Castaman G et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study. Molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease. Blood 2007; 109: 112 – 21.; Nichols WL, Hultin MB, James AH et al. von Willebrand disease (VWD): evidence‐based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14: 171 – 232.; James PD, Notley C, Hegadorn C et al. The mutational spectrum of type 1 von Willebrand disease. Results from a Canadian cohort study. Blood 2007; 109: 145 – 54.; Tosetto A, Castaman G, Rodeghiero F. Assessing bleeding in von Willebrand disease and bleeding score. Blood Rev 2007; 21: 89 – 97.; James AH, Konkle BA, Kouides P et al. Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis. Haemophilia 2015; 21: 81 – 7.; Kadir RA, Lee CA, Sabin CA, Pllard D, Economides DL. Pregnancy in women with von Willebrand’s disease or factor XI deficiency. Br J Obstet Gynaecol 1998; 105: 314 – 21.
-
3Academic Journal
المؤلفون: Sood, S. L., Cuker, A., Wang, C., Metjian, A. D., Chiang, E. Y., Soucie, J. M., Konkle, B. A.
مصطلحات موضوعية: Arthropathy, Factor VIII, Joint Range of Motion, Moderate Haemophilia A, Von Willebrand Factor, Von Willebrand's Disease, Oncology and Hematology, Health Sciences
وصف الملف: application/pdf
Relation: Sood, S. L.; Cuker, A.; Wang, C.; Metjian, A. D.; Chiang, E. Y.; Soucie, J. M.; Konkle, B. A. (2013). "Similarity in joint function limitation in Type 3 von Willebrand's disease and moderate haemophilia A." Haemophilia 19(4): 595-601.; https://hdl.handle.net/2027.42/98234; Haemophilia; Lillicrap D. Genotype/phenotype association in von Willebrand disease: is the glass half full or empty?. J Thromb Haemost 2009; 7 ( Suppl 1 ): 65 – 70.; Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest 1977; 60: 390 – 404.; Federici AB. Diagnosis of inherited von Willebrand disease: a clinical perspective. Semin Thromb Hemost 2006; 32: 555 – 65.; Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol 2000; 111: 1236 – 9.; Sumner M, Williams J. Type 3 von Willebrand disease: assessment of complications and approaches to treatment – results of a patient and Hemophilia Treatment Center Survey in the United States. Haemophilia 2004; 10: 360 – 6.; Ahlberg A, Silwer J. Arthropathy in von Willebrand's disease. Acta Orthop Scand 1970; 41: 539 – 44.; Von Willebrand EA. Hereditary pseudohaemophilia. Haemophilia 1999; 5: 223 – 31 discussion 2.; Sankarankutty M, Evans DI. Chronic arthropathy in von Willebrand's disease. Clin Lab Haematol 1983; 5: 149 – 56.; Abshire TC. Prophylaxis and von Willebrand's disease (vWD). Thromb Res 2006; 118 ( Suppl 1 ): S3 – 7.; Soucie JM, Forsyth A, Watson C, Wang C, U.D.C. Investigators. Joint Range of Motion (ROM) measurements in patients with von Willebrand disease compared with normal subjects. J Thromb Heamost 2007; 5 ( Suppl. 2 ): P‐W‐188.; Metjian AD, Wang C, Sood SL et al. Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease. Haemophilia 2009; 15: 918 – 25.; Soucie JM, Cianfrini C, Janco RL et al. Joint range‐of‐motion limitations among young males with hemophilia: prevalence and risk factors. Blood 2004; 103: 2467 – 73.; Fischer K, van der Bom JG, Mauser‐Bunschoten EP et al. Endogenous clotting factor activity and long‐term outcome in patients with moderate haemophilia. Thromb Haemost 2000; 84: 977 – 80.; Soucie JM, Wang C, Forsyth A et al. Range of motion measurements: reference values and a database for comparison studies. Haemophilia 2011; 17: 500 – 7.; Brinkmann T, Kahnert H, Prohaska W, Nordfang O, Kleesiek K. Synthesis of tissue factor pathway inhibitor in human synovial cells and chondrocytes makes joints the predilected site of bleeding in haemophiliacs. Eur J Clin Chem Clin Biochem 1994; 32: 313 – 7.; Berckmans RJ, Nieuwland R, Tak PP et al. Cell‐derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII‐dependent mechanism. Arthritis Rheum 2002; 46: 2857 – 66.; Valentino LA, Hakobyan N, Enockson C. Blood‐induced joint disease: the confluence of dysregulated oncogenes, inflammatory signals, and angiogenic cues. Semin Hematol 2008; 45: S50 – 7.; Berntorp E. Prophylaxis and treatment of bleeding complications in von Willebrand disease type 3. Semin Thromb Hemost 2006; 32: 621 – 5.; Berntorp E, Petrini P. Long‐term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis 2005; 16 ( Suppl 1 ): S23 – 6.; Berntorp E. Prophylaxis in von Willebrand disease. Haemophilia 2008; 14 ( Suppl 5 ): 47 – 53.; Federici AB. Prophylaxis of bleeding episodes in patients with von Willebrand's disease. Blood Transfus 2008; 6 ( Suppl 2 ): s26 – 32.; Federici AB, Gianniello F, Canciani MT, Mannucci PM Secondary long‐term prophylaxis in severe patients with von Willebrand's disease: an Italian cohort study. ASH Annual Meeting Abstracts 2005; 106: 1782.; Halimeh S, Krumpel A, Rott H et al. Long‐term secondary prophylaxis in children, adolescents and young adults with von Willebrand disease. Results of a cohort study. Thromb Haemost 2011; 105: 597 – 604.; Berntorp E, Abshire T. The von Willebrand disease prophylaxis network (vWD PN): exploring a treatment concept. Thromb Res 2006; 118 ( Suppl 1 ): S19 – 22.; Abshire TC, Federici AB, Alvarez MT et al. Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN). Haemophilia 2013; 19: 76 – 81.; Sadler JE, Budde U, Eikenboom JC et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103 – 14.; Nichols WL, Hultin MB, James AH et al. von Willebrand disease (VWD): evidence‐based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) expert panel report (USA). Haemophilia 2008; 14: 171 – 232.
-
4Academic Journal
المؤلفون: METJIAN, A. D., WANG, C., SOOD, S. L., CUKER, A., PETERSON, S. M., SOUCIE, J. M., KONKLE, B. A.
المصدر: Haemophilia ; volume 15, issue 4, page 918-925 ; ISSN 1351-8216 1365-2516